Publication Name	World Journal of Gastroenterology
Manuscript ID	5704
Country	Japan

Received	2013-09-22 15:27
Peer-Review Started	2013-09-22 18:11
First Decision by Editorial Office Director
Return for Revision	2013-10-20 21:52
Revised	2014-01-13 09:32
Publication Fee Transferred
Second Decision by Editor	2014-02-20 09:01
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-02-20 09:36
Articles in Press
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-03-03 14:34
Publish the Manuscript Online	2014-03-18 14:14

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality
Manuscript Source	Invited Manuscript
All Author List	Nobuyuki Toshikuni, Tomiyasu Arisawa and Mikihiro Tsutsumi
Funding Agency and Grant Number
Corresponding Author	Nobuyuki Toshikuni, MD, Department of Gastroenterology, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Ishikawa 920-0293, Japan. n.toshikuni@gmail.com
Key Words	Hepatitis C virus; Liver cirrhosis; Hepatic decompensation; Hepatocellular carcinoma; Mortality; Prevention; Interferon; Direct-acting antiviral agents
Core Tip	Liver cirrhosis (LC) is the critical stage of hepatitis C virus (HCV)-related chronic liver disease. Many studies of HCV-related LC patients have indicated that sustained virological response (SVR) after interferon therapy is highly associated with reductions in hepatic decompensation, hepatocellular carcinoma incidence, and mortality. Furthermore, direct-acting antiviral agents have shown excellent antiviral efficacy. Preliminary data have indicated that an interferon-free regimen achieved SVR for more than 50% of patients with LC due to HCV genotype 1. Branched-chain amino acid supplementation, improvement of insulin resistance, and the use of β-blockers for portal hypertension may also contribute to a reduction in liver-related complications.
Publish Date	2014-03-18 14:14
Citation	Toshikuni N, Arisawa T, Tsutsumi M. Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol 2014; 20(11): 2876-2887
URL	http://www.wjgnet.com/1007-9327/full/v20/i11/2876.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i11.2876

Full Article (PDF)	WJG-20-2876.pdf
Full Article (Word)	WJG-20-2876.doc
Manuscript File	5704-Review.doc
Answering Reviewers	5704-Answering reviewers.pdf
Copyright License Agreement	5704-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	5704-Language certificate.pdf
Peer-review Report	5704-Peer reviewer(s).pdf
Scientific Editor Work List	5704-Scientific editor work list.doc